News

Filter

Current filters:

tabalumabPharmaceutical

Product launches to fuel lupus market growth

28-02-2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase…

Anti-Arthritics/RheumaticsBenlystaBristol-Myers SquibbEli LillyepratuzumabGlaxoSmithKlineGlobalImmuPharmaLupuzorMerck SeronoOrenciaPharmaceuticalRituxanRochetabalumabUCB

Lack of efficacy causes Eli Lilly to drop Ph III RA program for tabalumab

08-02-2013

US drug major Eli Lilly (NYSE: LLY) says that it will discontinue the Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

Eli Lilly drops one tabalumab trial for RA

14-12-2012

US drug major Eli Lilly (NYSE: LLY) says that it will stop one of three Phase III rheumatoid arthritis…

Anti-Arthritics/RheumaticsEli LillyPharmaceuticalResearchtabalumab

COMPANY SPOTLIGHT

Menarini

Back to top